Skip to main content

Bronchiectasis Adult

2
Pipeline Programs
9
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
Aztreonam lysinePhase 41 trial
Active Trials
NCT03696290Terminated34Est. Mar 2025
Vast Therapeutics
Vast TherapeuticsNC - Morrisville
1 program
1
ALX1Phase 21 trial
Active Trials
NCT07731919Not Yet Recruiting28Est. Mar 2027
Baxter International
2 programs
Volara therapyN/A1 trial
Volara therapyN/A
Active Trials
NCT06937216Not Yet Recruiting10Est. Nov 2025
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
Aztreonam lysinePHASE_4
Aztreonam lysinePHASE_4
Bayer
BayerLEVERKUSEN, Germany
1 program
Group AN/A1 trial
Active Trials
NCT03383939Completed20Est. Sep 1999
ETS
ETSMO - Rolla
1 program
Over-night treatment with myAIRVO2N/A1 trial
Active Trials
NCT04102774Completed130Est. Jan 2025
Bilim Pharmaceuticals
Bilim PharmaceuticalsTurkey - Istanbul
1 program
pulmonary rehabilitationN/A1 trial
Active Trials
NCT07317531Not Yet Recruiting40Est. Mar 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Kite PharmaAztreonam lysine
Vast TherapeuticsALX1
Bilim Pharmaceuticalspulmonary rehabilitation
Baxter InternationalVolara therapy
ETSOver-night treatment with myAIRVO2
BayerGroup A

Clinical Trials (6)

Total enrollment: 262 patients across 6 trials

NCT03696290Kite PharmaAztreonam lysine

Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Start: Oct 2019Est. completion: Mar 202534 patients
Phase 4Terminated
NCT07731919Vast TherapeuticsALX1

Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis

Start: Sep 2026Est. completion: Mar 202728 patients
Phase 2Not Yet Recruiting
NCT07317531Bilim Pharmaceuticalspulmonary rehabilitation

Effects of Expiratory Muscle Training Added to Pulmonary Rehabilitation in Patients With Bronchiectasis

Start: Feb 2026Est. completion: Mar 202740 patients
N/ANot Yet Recruiting
NCT06937216Baxter InternationalVolara therapy

Evaluation of the Effectiveness of The Volara System Determined by Sputum Movement and Production

Start: May 2025Est. completion: Nov 202510 patients
N/ANot Yet Recruiting
NCT04102774ETSOver-night treatment with myAIRVO2

Effect of AIRVO Heated Humidification in Bronchiectasis

Start: Jun 2019Est. completion: Jan 2025130 patients
N/ACompleted
NCT03383939BayerGroup A

Inhaled A1AT in Adult Stable Bronchiectasis

Start: Jun 1996Est. completion: Sep 199920 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.